Back to results

The University of Arizona.

New paradigm for drug design: Design and synthesis of novel biologically active peptides that are agonists at opioid receptors and antagonists at cholecystokinin receptors

Abstract

dc:description.abstract

We now know from genomics that many disease states lead to changes in expressed proteins (adaptation/plasticity). Therefore, drug design and discovery based on normal states and single targets often is inadequate or even counter-indicated. Therefore, the "system changes" that have occurred must be considered in any treatment for the disease. Such "systems changes" are clearly evident in neuropathic pain where opioids can actually heighten pain. In these pain states there are increased levels of neurotransmitters such as cholecystokinin (CCK) in which both the peptides and their receptors are increased in pain states. To effectively treat diseases involving "systems changes" a new paradigm for the design of compounds was proposed. In this new approach single peptide or peptidomimetic molecules are designed to interact with multiple receptor targets. For the treatment of pain, a series of linear and cyclic peptides and peptidomimetics were designed based on the overlapping pharmacophores of opioid and CCK ligands. The CCK/opioid analogues were synthesized and evaluated for their biological activities. Several of the CCK/opioid analogues were found to simultaneously interact with opioid receptors as agonists and CCK receptors as antagonists. In addition, the lead compounds have been tested in several pain models and were found to be promising in the treatment of neuropathic pain. Further, the structure-activity relationships of these novel peptides have provided new insights into the requirements for binding and bioactivity at opioid and CCK receptors, as well as the overlapping pharmacophores of CCK and enkephalin.

Degree

thesis:*
Name thesis:degree_name
Ph.D.
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Graduate College
Grantor dc:publisher
The University of Arizona.
Year dc:date.issued
2003

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Agnes, Richard S
Advisor dc:contributor.advisor
  • Hruby, Victor J.

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/10150/280340
OAI identifier oai:identifier
oai:repository.arizona.edu:10150/280340

Chain of custody

source
Harvested from
University of Arizona
Base URL
repository.arizona.edu/oai/request
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Agnes, Richard S. New paradigm for drug design: Design and synthesis of novel biologically active peptides that are agonists at opioid receptors and antagonists at cholecystokinin receptors. doctoral thesis, The University of Arizona., 2003. http://hdl.handle.net/10150/280340